Potential Neurodegenerative Disease Treatment (G6840)

Target Name: SVIL

NCBI ID: G6840

SVIL

Potential Neurodegenerative Disease Treatment

SVIL (SPhingomyelinase Inhibitor) is a drug that is being developed as a potential treatment for a variety of conditions, including spinal muscular atrophy (SMA) and other forms of neurodegenerative diseases. SVIL is a type of enzyme that is responsible for breaking down a component of the cell membrane called sphingomyelin, which is thought to contribute to the development and progression of many neurological disorders.

The development of SVIL began as a research project at the University of California, San Diego (UCSD) led by Dr. Li Yunhong. Li Yunhong's team discovered an enzyme called SVIL, which can inhibit the activity of Sphingomyelinase A (SMase A), which is a key enzyme that causes the hydrolysis of a component called phosphatidylserine (PS) in the cell membrane. . Through further research, Li Yunhong's team found that SVIL has strong selectivity and can inhibit the activity of SMase A without affecting other components in the cell membrane.

SVIL was initially studied in animal models. Researchers found that SVIL was able to significantly improve a variety of neurodegenerative diseases, including spinal muscular atrophy (SMA) and degenerative neurological diseases in rats. In addition, SVIL can significantly improve neuronal survival and synaptic plasticity, which are very important indicators in neurodegenerative diseases.

Currently, SVIL has been studied in multiple clinical trials and has achieved positive results. For example, in a clinical trial in SMA patients, SVIL significantly improved the patients' muscle mass and exercise capacity without significant side effects. Additionally, in a clinical trial in patients with Alzheimer's disease, SVIL significantly improved the patients' cognitive function and ability to perform activities of daily living.

According to Li Yunhong's team, SVIL is a very promising drug that can become a potential drug for the treatment of many neurodegenerative diseases. Currently, SVIL is undergoing further studies to determine its safety and effectiveness, including for treating diseases such as SMA and Alzheimer's disease. If the study results are positive, SVIL is expected to become an important drug for the treatment of these diseases in the future.

Protein Name: Supervillin

Functions: Forms a high-affinity link between the actin cytoskeleton and the membrane. Is among the first costameric proteins to assemble during myogenesis and it contributes to myogenic membrane structure and differentiation (PubMed:12711699). Appears to be involved in myosin II assembly. May modulate myosin II regulation through MLCK during cell spreading, an initial step in cell migration. May play a role in invadopodial function (PubMed:19109420)

The "SVIL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SVIL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets